Related Experiment Video

Updated: Apr 12, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Automated insulin delivery use in children and adolescents with type 1 diabetes across the world

Sebastian Seget1, Ewa Rusak1, Julie Pelicand2

  • 1Department of Children's Diabetology and Lifestyle Medicine, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poland.

Diabetes Research and Clinical Practice
|April 10, 2026
PubMed

Insights

Automated insulin delivery (AID) systems significantly improved glycemic control in children and adolescents with type 1 diabetes (T1D). Real-world data show increased time in target glucose ranges and reduced hypoglycemia with AID therapy.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Diseases
  • Biomedical Engineering

Background:

  • Automated insulin delivery (AID) systems are emerging as a key technology for type 1 diabetes (T1D) management.
  • Real-world evidence on AID efficacy in pediatric populations is limited.
  • The SWEET registry provides a valuable international dataset for studying pediatric T1D care.

Purpose of the Study:

  • To evaluate the impact of AID therapy on glycemic outcomes in children and adolescents with T1D.
  • To assess changes in HbA1c, mean sensor glucose, and time in target glucose ranges before and after AID initiation.
  • To analyze real-world effectiveness of AID systems in a large, multinational pediatric cohort.

Main Methods:

  • An observational, comparative study design was employed, analyzing data from the SWEET registry.
  • Two 12-month periods (pre- and post-AID initiation) were compared for 2,170 children and adolescents (≤18 years) with T1D.
  • Primary endpoints included HbA1c, mean sensor glucose, and time in specific glycemic ranges (70-180 mg/dL and 70-140 mg/dL).

Main Results:

  • AID therapy led to significant improvements in glycemic control.
  • Time in target glucose ranges (70-180 mg/dL and 70-140 mg/dL) increased significantly.
  • Mean sensor glucose, glucose variability, and time below range (<70 mg/dL) decreased, while HbA1c improved without altering insulin dosage.

Conclusions:

  • AID therapy demonstrates significant effectiveness in improving glycemic outcomes for pediatric patients with T1D.
  • The study highlights reduced hypoglycemia and enhanced time in target ranges as key benefits of AID systems.
  • These findings support the integration of AID systems into routine pediatric diabetes care across diverse settings.
Abstract

Keywords:
AdolescentsAutomated insulin delivery SWEET databaseChildrenTime in rangeType 1 diabetes

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.4K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.6K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.3K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
143
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
129
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
254